ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2630

A Dutch Consensus Statement on the Diagnosis and Treatment of ANCA Associated Vasculitis

Ebru Dirikgil1, Peter Verhoeven 2, Sander Tas 3, Abraham Rutgers 4, Hein Bernelot Moens 5, Jacob van Laar 6, Willem Jan Bos 7 and Onno Teng 1, 1LUMC, Leiden, Netherlands, 2The Dutch Vasculitis Foundation, Silvolde, Netherlands, 3Amsterdam Rheumatology & immunology Center, Amsterdam UMC/University of Amsterdam, Amsterdam, Netherlands, 4University Medical Center Groningen, Groningen, Netherlands, 5Ziekenhuisgroep Twente, Almelo, Netherlands, 6UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, 7St. Antoniusziekenhuis, Nieuwegein, Netherlands

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: ANCA, healthcare management and quality improvement, Vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Session Title: Vasculitis – ANCA-Associated Poster I

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Several guidelines have been published on the diagnosis and treatment of anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV). These guidelines provide an evidence-based approach to support clinical-decision making and adequate implementation is needed to improve care. As part of an implementation strategy, national consensus meetings in the Netherlands were initiated in order to establish consensus on broad aspects of the diagnosis and treatment of AAV based upon the recently published guidelines, relevant to daily clinical practice.

Methods: A national, multidisciplinary working group of physicians (nephrologists, rheumatologists, immunologists, pulmonologist, pathologist) with expertise on AAV addressed the broad spectrum of diagnosing, treating and organisation of care for AAV patients. Consensus was established using a Delphi-based method in a national conference in conjunction with a nationally distributed online consensus survey.  This survey was distilled from the current published international guidelines. Cut-off for consensus was 70% (dis-)agreement.

Results: Ninety-eight professionals were involved in the Delphi procedure to assess consensus on 52 statements regarding diagnosis, treatment and organisation of care for AAV patients. From 52 statements, consensus was achieved for 39 statements (75%). Consensus was achieved on aspects of AAV disease definition, nomenclature, distinct disease states through follow-up, treatment algorithm and organisation of care for AAV. No consensus was achieved on the necessity of histopathological evidence, regular blood testing for ANCAs and standard BVAS, VDI and PROMs assessment.

Conclusion: This study describes the results of a national consensus statement on diagnosing and treatment of AAV patients as part of an implementation strategy in the Netherlands of (inter-)national guideline-derived recommendations. Future studies should evaluate whether the consensus statement has facilitated local implementation, reduced clinical practice variation and, ultimately, improved care for AAV patients in the Netherlands.


Disclosure: E. Dirikgil, None; P. Verhoeven, None; S. Tas, None; A. Rutgers, None; H. Bernelot Moens, None; J. van Laar, Roche, 2, 8, Arthrogen, 5, Thermofisher, 2, BMS, 8, MSD, 2, Eli Lilly, 8, Gesynta, 5, Leadiant, 5, Arxx Tx, 5, Astra Zeneca, 2, Sanofi, 8; W. Bos, None; O. Teng, None.

To cite this abstract in AMA style:

Dirikgil E, Verhoeven P, Tas S, Rutgers A, Bernelot Moens H, van Laar J, Bos W, Teng O. A Dutch Consensus Statement on the Diagnosis and Treatment of ANCA Associated Vasculitis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/a-dutch-consensus-statement-on-the-diagnosis-and-treatment-of-anca-associated-vasculitis/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-dutch-consensus-statement-on-the-diagnosis-and-treatment-of-anca-associated-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences